BridgeBio's Oral Infigratinib Shows Benefits Beyond Growth Achondroplasia Phase 3 PROPEL 3 Trial

H.C. Wainwright reiterated a Buy rating on BridgeBio Pharma (BBIO) with a $120 price target, citing favorable data from a Phase 3 study. BBIO shares are up 44% over the past year, with revenue surging 202% in the last twelve months. The company reported Q2 2026 revenue of $243.7 million, exceeding estimates. Analysts from Piper Sandler, Canaccord, and Mizuho also raised their price targets.

BridgeBio (BBIO) reported Phase 3 study data showing some acoramidis-treated patients had cardiac improvements. 54% showed left ventricular function improvement at 30 months, per completer analysis. Separate analysis found 34% improvement. Treatment also reduced days lost to death or hospitalization. BridgeBio plans a Phase 3b/4 study to further evaluate acoramidis.

President Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.

President Trump expanded his Most-Favored-Nation drug pricing initiative to 26 companies, covering 89% of the branded drug market. New participants include Alcon, Astellas Pharma, and Teva, among others, agreeing to tie Medicaid drug prices to those in other developed countries. The deals also involve $19.6 billion in U.S. manufacturing investments. According to HHS Secretary Robert F. Kennedy Jr., the agreements cover nine out of 10 drugs used by Americans.

Nine mid-sized pharma companies, including Teva, signed MFN pricing deals with the White House, covering 89% of the US branded drug market. The policy ties US drug prices to the lowest prices charged abroad. The administration claims the deals will reduce prices for costly, chronic, and rare diseases and secure $20B in US manufacturing investments. Public Citizen criticizes the deals as ineffective.

President Trump announced drug pricing agreements with nine pharmaceutical companies, including Alcon (ALC), BeOne (ONC), BridgeBio (BBIO), and Teva (TEVA). The deals require discounts on outpatient drugs for Medicaid and $19.6B in U.S. manufacturing investments. This expands the total to 26 companies, covering 90% of the U.S. market. The White House estimates $529B in savings over a decade.